New MRI scans could reveal hidden lung changes in cystic fibrosis patients
NCT ID NCT04391322
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses advanced MRI scans to track lung structure and function in people with cystic fibrosis who are taking CFTR-modulator therapy. Researchers will compare MRI results with standard breathing tests and quality-of-life measures. The study includes healthy volunteers, stable CF patients, and children as young as 4 starting triple combination therapy. The goal is to see if MRI can detect treatment effects better than current methods.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could show that MRI is a better way to monitor lung health in cystic fibrosis patients on modulator therapy.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and MRI results may not match standard breathing tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 86 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2020
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study includes four populations of interest: Group 1: 25 healthy volunteers, Group 2: 25 patients with stable CF lung disease and Group 3: 20 patients with CF lung disease anticipated to receive treatment with CFTR-modulator therapy and Group 4: 18 patients with CF who are between 4-8 years old and are starting triple combination modulator therapy using the rapid lung and abdominal imaging methods
- Ages
-
4 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants must be greater than or equal to 4 years of age * Informed consent by patient or parent/guardian consent and participant assent when appropriate. * Able to perform reproducible spirometry and achieve a breath hold duration sufficient for MRI acquisition Exclusion Criteria: * Medical instability that would preclude the ability to undergo the required investigations * FEV1 % predicted \< 40% * Severe claustrophobia * Does not meet MRI screening criteria * Cough within the past 3 days prior to study visit * Usage of oral antibiotics within 3 weeks prior to study visit
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?